The Territoriality Trap: Why a US Patent Win Means Nothing Where the Molecule Was Never Filed
On October 2, 2023, the Patent Trial and Appeal Board refused to institute Mylan’s inter partes review of two Novo
Why a Drug Off-Patent in Europe Can Still Be Protected for Three More Years in the US
On October 16, 2018, adalimumab biosimilars went on sale across Germany, France and the rest of the European Union. On
Why a Drug Off-Patent in Europe Can Still Be Protected for Three More Years in the US Read Post »
Your 340B Contract Pharmacy Network Is Working Off a Different Generic Entry Date Than Your Legal Team
DrugPatentWatch tracks generic entry dates for a living, and one pattern shows up over and over in support calls from
Shelved, Not Failed: How AI Finds the Medicines Pharma Abandoned on Purpose
A drug that never reaches patients usually did not fail a safety test. In a systematic review of 115 published
Shelved, Not Failed: How AI Finds the Medicines Pharma Abandoned on Purpose Read Post »
Three Clocks, One Patent: The Extension Gap Between Australia, Canada, and the EU
Abilify Maintena lost its patent-based market exclusivity in the European Union and the United States in October 2024 [1][2]. In
Three Clocks, One Patent: The Extension Gap Between Australia, Canada, and the EU Read Post »
Someone Else Found a New Use for Your Drug. Here’s What Happens Next.
In 2006, a Boston jury ordered Eli Lilly to pay roughly $65 million in back royalties, plus a 2.3% running
Someone Else Found a New Use for Your Drug. Here’s What Happens Next. Read Post »
The Radioligand Therapy Patent Land Grab: Why Pluvicto’s IP Strategy Is the New Template
On June 17, 2026, a federal judge in Delaware ruled that every Lutathera patent Novartis had asserted against two rivals
The Radioligand Therapy Patent Land Grab: Why Pluvicto’s IP Strategy Is the New Template Read Post »
We Pulled 18 Years of FTC Settlement Data on ANDA Litigation. Verdicts Are the Exception.
On January 8, 2025, Catalyst Pharmaceuticals told the SEC that it had settled patent litigation over Firdapse with Teva Pharmaceuticals.
The Procurement Team That Waits for the Generic Announcement Already Lost the Negotiation
The Short Answer AbbVie and Amgen disclosed Humira’s U.S. biosimilar entry date — January 31, 2023 — on September 28,
